SOLICITATION NOTICE
B -- Sample labeling/bisulphate treatment, methylation-specific amplification, quality control, sequence analysis (pyrosequencing) of bisulphate treated DNA, determination of allele-specific expression (DNA and RNA), data extraction and processing, and segment
- Notice Date
- 9/3/2010
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100201-AV
- Archive Date
- 9/25/2010
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Epidemiology and Biostatistics Program (EBP), Genetic Epidemiology Branch (GEB), plans to procure services regarding sample labeling/bisulphate treatment, methylation-specific amplification, quality control, sequence analysis (pyrosequencing) of bisulphate treated DNA, determination of allele-specific expression (DNA and RNA), data extraction and processing, and segmentation analysis on DNA (and RNA) samples extracted from the blood of subjects in melanoma-prone families. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.5 to use simplified procedures for commercial acquisitions. The North American Industry Classification System Code is 621511 and the business size standard is $12.5M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance for this procurement shall be for twelve months from date of award. The NCI Division of Cancer Epidemiology and Genetics is currently investigating the relationship between CDKN2A mutations and their association with high risk of cutaneous malignant melanomas (CMM). However, the incomplete penetrance of CDKN2A suggests that additional factors modify the effect of this gene in melanoma-prone families. Further, phenotypic manifestations, such as age at diagnosis, presence/number of dysplastic nevi (DN), number of melanomas, and co-segregation of pancreatic cancer, vary significantly among mutation carriers even within a single family. These findings suggest that other genetic factors or downstream epigenetic mechanisms may be associated with risk of CMM or may modify the effect of CDKN2A. The GEB has been using a variety of genetic and more recently epigenetic approaches to identify such factors. As part of an ongoing epigenome project the lab is examining genome-wide CpG island methylation, miRNA profiling and total gene expression levels as well as chromatin modifications in the melanoma-prone families segregating CDKN2A germline mutations. The Government shall ship the DNA and RNA blood samples to the Contractor immediately following the date of award. The contractor shall complete the following tasks upon receipt of the samples: 1. LINE-1 repetitive sequence methylation on 400 samples using pyrosequencing as a proxy for global methylation in melanoma family members to identify and compare global LINE-1 DNA methylation patterns in the GEB melanoma family subjects with and without CDKN2A carrier mutations and/or with or without melanoma. LINE-1 methylation will be carried out using and optimized bisulphate modification, PCR and pyrosequencing assay. 2. Promoter methylation-specific PCR (MS-PCR) on 15 candidate genes: CDKN2A, MAGE3, PTEN, DAPK, TNFSF10C, LOX, p14ARF, RASSF1A, CDH1, COL1A2, NPM2, HSPB6, DDIT4L, MTIG and TNFSD10D on all 400 samples. All of these gene targets have previously been shown to be associated with familial CMM. 3. Allele-specific expression (ASE) analyses of the CDKN2A locus from 150 samples with and without CDKN2A carrier mutations and/or with or without melanoma using pryrosequencing of cDNA and DNAs (and specific SNPs to identify and quantify the allelic message). 4. Results shall be provided to the NCI Contracting Officer's Technical Representative (COTR) in MS-Excel with all identifiers removed Potential offerors may request a copy of the solicitation from Ashley Virts, Contract Specialist via electronic mail at virtsa@mail.nih.gov or fax (301) 402-4513 by September 10, 2010 11 AM EST. Interested parties shall include the name of company; complete mailing address; point of contacts, phone, fax numbers, and email address; company DUNS number and business size. All questions shall be in writing and addressed to the Contract Specialist noted above. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: RFQ-NCI-100201-AV on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100201-AV/listing.html)
- Record
- SN02267548-W 20100905/100903235028-e450ceff2fa746ec7878d38cea0b11fc (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |